Advaxis

Advaxis is a biopharmaceutical company founded by Yvonne Paterson on January 1, 2002. The company is headquartered in Princeton, New Jersey, United States. Advaxis specializes in the development of immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company operates with a licensing business model and primarily serves the B2B market.

Advaxis is a publicly traded company listed on the Nasdaq stock exchange under the symbol ADXS. The company has raised a total funding amount of $4,473,673 USD as of its latest funding round on May 29, 2012. Advaxis competes with companies such as Good Natured Products Inc. in the biopharmaceutical industry.

The company has been assigned five patents in the field of immunotherapy and vaccine development. Advaxis focuses on biomedical engineering and biotechnology to develop innovative treatments for various diseases.

Kenneth A. Berlin serves as the CEO of Advaxis, while James Patton and Kenneth A. Berlin are members of the company's board of directors .

Advaxis maintains an official website at http://advaxis.com and is active on various social media platforms, including Twitter (http://www.twitter.com/advaxis) , LinkedIn (https://www.linkedin.com/company/advaxis-inc-/about/) , and Facebook (https://www.facebook.com/advaxisinc) . The company also has a presence on AngelList (https://angel.co/advaxis) and Crunchbase (https://www.crunchbase.com/organization/advaxis-inc) .